指南与共识腹部介入CTMRUSDSA

加拿大共识声明:确立中晚期肝细胞癌局部与全身治疗的角色

Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada.
指南 / 共识 · Cancer Treat Rev · 2023-03-02

针对中晚期肝细胞癌治疗选择快速演变且缺乏加拿大本土推荐,泛加拿大多学科专家组采用改良Delphi框架制定共识。

要点

  • 共识覆盖中晚期HCC多学科治疗、动脉内治疗、生物制剂、放疗、手术及消融六大领域。
  • 治疗选择扩展支持更个体化策略,并在更广泛疾病场景中向治愈意图转变。

局限性

  • 共识基于改良Delphi框架和专家意见,非系统评价或高级别证据直接得出。
  • 推荐针对加拿大医疗背景,外推至其他医疗体系需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Hepatocellular carcinoma (HCC) a leading cause of cancer mortality worldwide and approximately one-third of patients present with intermediate-stage disease. The treatment landscape of intermediate-stage HCC is rapidly evolving due to developments in local, locoregional and systemic therapies. Treatment recommendations focused on this heterogenous disease stage and that take into account the Canadian reality are lacking. To address this gap, a pan-Canadian group of experts in hepatology, transplant, surgery, radiation therapy, nuclear medicine, interventional radiology, and medical oncology came together to develop consensus recommendations on management of intermediate-stage HCC relevant to the Canadian context.

METHODS: A modified Delphi framework was used to develop consensus statements with strengths of recommendation and supporting levels of evidence graded using the AHA/ACC classification system. Tentative consensus statements were drafted based on a systematic search and expert input in a series of iterative feedback cycles and were then circulated via online survey to assess the level of agreement.

RESULTS & CONCLUSION: The pre-defined ratification threshold of 80 % agreement was reached for all statements in the areas of multidisciplinary treatment (n = 4), intra-arterial therapy (n = 14), biologics (n = 5), radiation therapy (n = 3), surgical resection and transplantation (n = 7), and percutaneous ablative therapy (n = 4). These generally reflected an expansion in treatment options due to developments in previously established or emergent techniques, introduction of new and more active therapies and increased therapeutic flexibility. These developments have allowed for greater treatment tailoring and personalization as well as a paradigm shift toward strategies with curative intent in a wider range of disease settings.

来源:Cancer Treat Rev,查看原文。版权归原作者所有。

引用

  1. Wong, Lim, Tam, et al. Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treat Rev. 2023. PMID: 36924644. doi:10.1016/j.ctrv.2023.102526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。